- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068444
The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. The purposes of this study are:
1. Primary aims:
- Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests.
- Evaluation of clinical safety of Pioglitazone
2. Secondary aims:
- Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.
- The impact of Pioglitazone on the related metabolic index, including insulin resistance(HOMA-IR), newly-onset diabetes, metabolic syndrome, lipid profiles (T-Chol, HDL-C, LDL-C, TG).
- Comparison between Pioglitazone and placebo groups in terms of high-sensitive C-reactive protein changes.
3. Interventional aim: Assessment the association between magnetic resonance imaging study and intrahepatic fat distribution before and after Pioglitazone treatment.
Study Overview
Detailed Description
Pioglitazone belongs to thiazolidinediones and anti-diabetes drug which decreases the insulin resistance. It increases the use of glucose of peripheral tissues and decrease the production of glucose from liver and dose not influence the production of insulin. It is agonist of peroxisome proliferator-activated receptor-gamma (PPARγ) and by binding to the receptors of PPARγ in various tissues it has effects on transcription of the insulin-dependent gene. In animal model, pioglitazone has shown to influence the metabolism by the insulin-dependent mechanism.
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. Meanwhile, PPARγ could also prevent the development of alcohol-induced steatohepatitis, improve hepatic necroinflammatory activity, and decrease lipid deposition. It is not yet clearly known how the effect of P-PARγ agonist among Asian peoples.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 803
- Kaohsiung Medical University Hospital
-
Kaohsiung City, Taiwan, 812
- Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main inclusion criteria:
- Male and female patients with 18-70 years of age
- Liver biopsy findings consistent with the diagnosis of NASH with or without compensated cirrhosis within one year before baseline
- Compensated liver disease
- Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- All fertile males and females must be using two forms of effective contraception during treatment during the 3 months after treatment.
- ALT level between 1.3-5 x ULN for 2 occasions during 6 months before screening.
- HbA1C ≦ 8.0 during screening
Main exclusion criteria:
- Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) *6 months before baseline.
- History or other evidence of a medical condition associated with chronic liver disease other than NASH (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, > 20 g/day for female or > 40 g/day for male, toxin exposures)
- hepatocellular carcinoma
- History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- Serum creatinine level >1.5 times the upper limit of normal at screening and calculated creatinine clearance as calculated by Cockcroft and Gault < 60mL/min during screening
- History of ischemic heart disease during screening
- New York Heart Association (NYHA) Functional Class 1-4 cardiac status during screening
- Albumin <3.2g/dL during screening
- Total bilirubin >1.2 x ULN during screening. Patients with history of asymptomatic indirect hyperbilirubinemia whose total bilirubin < 2 x ULN and direct bilirubin < 20% of total bilirubin could be included.
- History of prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3
- Organ, stem cell, or bone marrow transplant
- History of serious concurrent medical illness that in the investigator's opinion might interfere with therapy this includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis
- Active systemic autoimmune disorder
- Pregnancy (or lactation) or, in subjects capable of bearing children, inability / unwillingness to practice adequate contraception
- Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit
- Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days prior to screening.
- Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 6 weeks of the screening visit
- Current therapy with insulin within 1 week prior to screening.
- Experienced use with PPARg agonist (e.g., rosiglitazone, pioglitazone) within 6 months prior to screening.
- Known hypersensitivity to any component of PPARg agonists
- A history of hepatotoxicity to TZDs and/or a history of severe edema or a medically serious fluid-related event associated with the use of TZDs
- History of metformin use within 3 months prior to screening.
- Type Ⅰ diabetes
- Seropositive of HBsAg, anti-HCV or anti-HIV during screening or 3 month prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone
Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
|
Other Names:
|
Placebo Comparator: Placebo
Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
|
placebo 30 mg/d for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests
Time Frame: 9 months
|
9 months
|
Evaluation of clinical safety of Pioglitazone
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wan-Long Chuang, MD, PhD, Kaohsiung Medical University
Publications and helpful links
General Publications
- Huang JF, Dai CY, Huang CF, Tsai PC, Yeh ML, Hsu PY, Huang SF, Bair MJ, Hou NJ, Huang CI, Liang PC, Lin YH, Wang CW, Hsieh MY, Chen SC, Lin ZY, Yu ML, Chuang WL. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int. 2021 Oct;15(5):1136-1147. doi: 10.1007/s12072-021-10242-2. Epub 2021 Aug 12.
- Huang JF, Yeh ML, Huang CF, Huang CI, Tsai PC, Tai CM, Yang HL, Dai CY, Hsieh MH, Chen SC, Yu ML, Chuang WL. Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. PLoS One. 2017 May 4;12(5):e0174394. doi: 10.1371/journal.pone.0174394. eCollection 2017.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KMUH-HB9608
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis
-
University of Maryland, BaltimoreAlexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... and other collaboratorsTerminatedAcute Hepatitis C | Acute Hepatitis B | Acute Hepatitis A | Acute Hepatitis E | Acute EBV Hepatitis | Acute CMV HepatitisEgypt
-
Gilead SciencesCompletedChronic Hepatitis DeltaFrance, Moldova, Republic of, Romania, Russian Federation
-
Ziauddin HospitalUnknown
-
National Taiwan University HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanUnknownChronic Hepatitis B | Chronic Hepatitis DTaiwan
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Beijing Kawin Technology Share-Holding Co., Ltd.CompletedChronic Hepatitis cChina
-
Eiger BioPharmaceuticalsCompleted
-
Sohag UniversityRecruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States